Acadia Pharmaceuticals Inc.

ACADIA PHARMACEUTICALS INC is a biopharmaceutical company focused on developing innovations for underserved neurological and rare disease communities globally. The company operates with two core franchises: neurological disease and rare disease. Its neurological disease franchise is centered on NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. Food and Drug Administration (FDA) for treating hallucinations and delusions associated with Parkinson's disease psychosis (PDP). The rare disease franchise is anchored by DAYBUE, the first and only drug approved for the treatment of Rett syndrome. Net product sales from NUPLAZID and DAYBUE combined were $1,071.5 million for 2025, an increase from $957.8 million for 2024. Beyond these commercial products, ACADIA PHARMACEUTICALS INC maintains a portfolio of product candidates and research programs aimed at significant unmet medical needs in neurological and rare diseases. The most advanced product candidate is remlifanserin (formerly ACP-204), which is being developed for Alzheimer's disease psychosis (ADP) and Lewy Body Dementia Psychosis (LBDP). A Phase 2 study evaluating remlifanserin for hallucinations and delusions associated with ADP was initiated in November 2023. An additional Phase 2 study of remlifanserin in LBDP began in September 2025. In the fourth quarter of 2025, the company initiated a Phase 2 study of ACP-211 for the treatment of major depressive disorder (MDD). Several other product candidates are in earlier stages of development for neurological and rare diseases.